BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Nivolumab

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 101

Registration Number: NCT06735781

Locations: 🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Hospices Civils de Lyon, Lyon, France

and more 4 locations

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986490
Drug: Bevacizumab

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 360

Registration Number: NCT06730750

Locations: 🇺🇸
Local Institution - 0007, Los Angeles, California, United States
🇺🇸
Local Institution - 0017, Grand Rapids, Michigan, United States
🇺🇸
Local Institution - 0004, Hackensack, New Jersey, United States

and more 3 locations

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

Phase 1

Not yet recruiting

Conditions: Kidney Failure, Chronic
Healthy Volunteers
Renal Impairment

Interventions: Drug: BMS-986278

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT06723535

Locations: 🇺🇸
Local Institution - 0003, Miami, Florida, United States
🇺🇸
Local Institution - 0002, Miami, Florida, United States
🇺🇸
Local Institution - 0004, Orlando, Florida, United States

and more 1 locations

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

Phase 1

Not yet recruiting

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986278 Batched method, Dose A
Drug: BMS-986278 Batched method, Dose B
Drug: BMS-986278 Continuous method

First Posted Date: 2024-12-04

Last Posted Date: 2024-12-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT06715683

A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: Deucravacitinib
Drug: Systemic psoriasis medications
Other: No systemic medications

First Posted Date: 2024-11-28

Last Posted Date: 2024-11-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 833

Registration Number: NCT06710470

Locations: 🇺🇸
Bristol-Meyers Squibb, Lawrenceville, New Jersey, United States

A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

Not yet recruiting

Conditions: Psoriasis

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 350

Registration Number: NCT06701513

Locations: 🇫🇷
Hôpital Larrey, CHU Toulouse, Toulouse, France

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Idecabtagene vicleucel

First Posted Date: 2024-11-21

Last Posted Date: 2024-12-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT06698887

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeonranamdo, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of

and more 2 locations

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986482
Drug: Nivolumab and rHuPH20
Drug: Nivolumab/relatlimab/rHuPH20
Drug: Bevacizumab

First Posted Date: 2024-11-20

Last Posted Date: 2024-12-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 413

Registration Number: NCT06697197

Locations: 🇺🇸
Local Institution - 0030, Los Angeles, California, United States
🇺🇸
Local Institution - 0005, Irvine, California, United States
🇺🇸
Local Institution - 0008, Aurora, Colorado, United States

and more 4 locations

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors With Homozygous MTAP Deletion

Interventions: Drug: BMS-986504
Drug: [14C]-BMS-986504

First Posted Date: 2024-11-04

Last Posted Date: 2024-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT06672523

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3

Not yet recruiting

Conditions: Extensive-Stage Small Cell Lung Cancer

Interventions: Biological: BMS-986489 (BMS-986012+Nivolumab)
Biological: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2024-10-17

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 530

Registration Number: NCT06646276

Locations: 🇨🇳
Local Institution - 0335, Xi'an, Shaanxi, China
🇺🇸
Local Institution - 0245, Fort Myers, Florida, United States
🇺🇸
Local Institution - 0009, Orange City, Florida, United States

and more 150 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy